dyphylline (Dilor, Lufyllin)
Classes: Xanthine Derivatives; Phosphodiesterase Enzyme Inhibitors, Nonselective
Dosing and uses of Dilor, Lufyllin (dyphylline)
Adult dosage forms and strengths
tablet
- 200mg
- 400mg
Asthma/Reversible Bronchospasm
Up to 15 mg/kg PO q6hr PRn
Reduce in renal impairment
Renal Impairment
CrCl >50 mL/min: Administer 75% of normal dose
CrCl 10-50 mL/min: Administer 50% of normal dose
CrCl < 10 mL/min: Administer 25% of normal dose
Hepatic Impairment
Not studied
Pediatric dosage forms and strengths
Safety & efficacy not established
Dilor, Lufyllin (dyphylline) adverse (side) effects
Frequency not defined
Mild & infrequent
Headache
Nausea
Circulatory failure
Irritability
Ventricular arrhythmia
Hypotension
Tachycardia
Hyperglycemia
Muscle twitching
Albuminuria
Diuresis
Hematuria
Tachypnea
Restlessness
Seizure
Palpitation
Extrasystoles
Insomnia
Upset stomach
Warnings
Contraindications
Hypersensitivity to dyphylline or other xanthines
Cautions
Use caution in severe cardiac disease, HTN, hyperthyroidism, acute myocardial injury, peptic ulcer disease, renal impairment
Not for status asthmaticus
Pregnancy and lactation
Pregnancy category: C
Lactation: Excreted in breast milk; use with caution
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Dilor, Lufyllin (dyphylline)
Mechanism of action
Bronchodilator; also exhibits peripheral vasodilatory and bronchial smooth muscle relaxant activity
Pharmacokinetics
Peak plasma time: 45 min
Peak plasma:concentration: 1 g dose: 17 mcg/mL
Half-Life: 2 hr
Absorption: Rapid
Metabolism: not metabolized
Excretion: Urine (88%)